An Open Label, Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Continuous Twice-daily Oral Treatment of Nintedanib in Japanese Patients With Hepatocellular Carcinoma.

The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy

本研究旨在探讨无法接受根治性手术或局部区域治疗的日本肝细胞癌患者的安全性、耐受性、有效性及药代动力学（Pharmacokinetics，PK）。